PhaseⅠStudy of the HS-10241 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
HS-10241 is a highly potent and selective small molecule inhibitor of c-Met kinase. In
preclinical studies, it demonstrated strong activity against c-Met kinase in vitro and in
vivo, and inhibited tumor cell growth. This study is conducted to assess the maximum
tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the pharmacokinetics,
safety and preliminary anti-tumor activity of HS-10241 at single dose and multiple doses.